Observational Study on Treatment of SRD-Type Diabetic Macular Edema With Aflibercept
Abstract To examine the changes before and after intravitreal injection of Aflibercept in patients with SRD- type DME compared with non-SRD-type DME patients. Fifty eyes with SRD-type DME and 50 eyes with non-SRD-type DME were treated with Aflibercept (2 mg, 3 + PRN). The concentration of IL-6 in aqueous humor was measured before treatment, at 3 and 6 months after treatment. The changes in VA, CFT, and HRDs were observed before treatment and at 1, 2, 3, 4, 5, and 6 months after treatment. The VA in the two groups was improved after treatment (P < 0.05). the CFT and the number of HRDs in the two groups after treatment were decreased compared to that before treatment (all P < 0.05). Moreover, the concentration of IL-6 in the aqueous humor at 3 and 6 months after treatment was reduced compared with that before treatment (P < 0.05). This data suggests that inflammation had an important role in DME occurrence, and the occurrence of SRD is closely related to inflammation. Intravitreal injection of Aflibercept can improve the visual acuity and macular edema in patients with DME.